"randomised, multicentre, double-blind, placebo-controlledstudy of ambrisentan in subjects with inoperable chronicthromboembolic pulmonary hypertension (CTEPH)"

drug protocol number
AMB115811
drug sponsor
GSK
drug study
Ambrisentan 5 mg
drug trial site
N\A
drug status
Terminated
drug phase